{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Multi-Dose+PK+Phase+-+Daily+Group",
    "query": {
      "intervention": "Multi-Dose PK Phase - Daily Group"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Multi-Dose+PK+Phase+-+Daily+Group&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T08:43:06.367Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07755618",
      "title": "Characterization of Doxycycline Pharmacokinetics and Adherence",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sexually Transmitted Infection"
      ],
      "interventions": [
        {
          "name": "Single-Dose PK Phase - DR Group",
          "type": "DRUG"
        },
        {
          "name": "Single-Dose PK Phase - IR Group",
          "type": "DRUG"
        },
        {
          "name": "Multi-Dose PK Phase - Daily Group",
          "type": "DRUG"
        },
        {
          "name": "Multi-Dose PK Phase - Intermittent Group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HIV Prevention Trials Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2026-08-01",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07755618"
    },
    {
      "nct_id": "NCT02372084",
      "title": "A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "osilodrostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 33,
      "start_date": "2015-04-21",
      "completion_date": "2016-05-19",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02372084"
    },
    {
      "nct_id": "NCT06533280",
      "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Part A, C and D: VH3739937 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A: VH3739937 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A and C: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment E",
          "type": "DRUG"
        },
        {
          "name": "Part D: Probe cocktail",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-02",
      "completion_date": "2024-08-14",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533280"
    },
    {
      "nct_id": "NCT03333824",
      "title": "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CYP1A2 (caffeine)",
          "type": "DRUG"
        },
        {
          "name": "CYP2C19 (omeprazole)",
          "type": "DRUG"
        },
        {
          "name": "CYP3A (midazolam)",
          "type": "DRUG"
        },
        {
          "name": "Kytril (granisetron)",
          "type": "DRUG"
        },
        {
          "name": "Wee-1 kinase inhibitor AZD1775",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 33,
      "start_date": "2017-12-01",
      "completion_date": "2019-01-22",
      "has_results": false,
      "last_update_posted_date": "2019-03-25",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 7,
      "location_summary": "Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more",
      "locations": [
        {
          "city": "Bingham Farms",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03333824"
    },
    {
      "nct_id": "NCT05966324",
      "title": "Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "baxdrostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 41,
      "start_date": "2022-07-05",
      "completion_date": "2022-09-20",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05966324"
    },
    {
      "nct_id": "NCT05162053",
      "title": "PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "vicagrel Capsules",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jiangsu vcare pharmaceutical technology co., LTD",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 128,
      "start_date": "2021-12-09",
      "completion_date": "2022-11-03",
      "has_results": false,
      "last_update_posted_date": "2023-11-03",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Kansas City, Missouri",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162053"
    },
    {
      "nct_id": "NCT06247345",
      "title": "A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ADEL-Y01 - healty participants",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Healthy Participants",
          "type": "DRUG"
        },
        {
          "name": "ADEL-Y01 - MCI/AD",
          "type": "DRUG"
        },
        {
          "name": "Placebo - MCI/AD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alzheimer's Disease Expert Lab (ADEL), Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 42,
      "start_date": "2024-02-06",
      "completion_date": "2026-01-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lady Lake",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06247345"
    },
    {
      "nct_id": "NCT06679829",
      "title": "A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2024-11-06",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06679829"
    },
    {
      "nct_id": "NCT05043766",
      "title": "Evaluation of Oral PF614 Relative to OxyContin (PF614-102)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PF614",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "OxyContin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ensysce Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 84,
      "start_date": "2021-09-08",
      "completion_date": "2022-03-21",
      "has_results": false,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05043766"
    },
    {
      "nct_id": "NCT01915576",
      "title": "Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BAY1125976",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2013-09",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-28",
      "last_synced_at": "2026-09-08T08:43:06.367Z",
      "location_count": 4,
      "location_summary": "Santa Monica, California • Boston, Massachusetts • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01915576"
    }
  ]
}